Pfizer Inc. $PFE Shares Bought by Phoenix Financial Ltd.

Phoenix Financial Ltd. raised its position in Pfizer Inc. (NYSE:PFE) by 98.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 152,172 shares of the biopharmaceutical company’s stock after buying an additional 75,569 shares during the quarter. Phoenix Financial Ltd.’s holdings in Pfizer were worth $3,878,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Brighton Jones LLC lifted its position in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. ORG Partners LLC raised its position in Pfizer by 17.3% during the 2nd quarter. ORG Partners LLC now owns 4,013 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 593 shares during the last quarter. GC Wealth Management RIA LLC lifted its stake in shares of Pfizer by 46.4% in the 2nd quarter. GC Wealth Management RIA LLC now owns 24,012 shares of the biopharmaceutical company’s stock worth $582,000 after acquiring an additional 7,611 shares during the period. Finally, Archford Capital Strategies LLC boosted its holdings in shares of Pfizer by 24.8% in the second quarter. Archford Capital Strategies LLC now owns 19,587 shares of the biopharmaceutical company’s stock valued at $475,000 after acquiring an additional 3,886 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Pfizer stock opened at $26.49 on Wednesday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The firm has a market capitalization of $150.61 billion, a PE ratio of 15.40 and a beta of 0.47. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The firm’s 50-day simple moving average is $25.43 and its 200 day simple moving average is $25.01.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 100.00%.

Analysts Set New Price Targets

A number of brokerages recently commented on PFE. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Scotiabank initiated coverage on Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price for the company. HSBC restated a “buy” rating and issued a $29.00 price target on shares of Pfizer in a research note on Wednesday, December 10th. Morgan Stanley cut their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.06.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on PFE to $27 from $24, giving the stock an analyst-driven lift today. Why Is Pfizer Stock Rising Tuesday?
• Positive Sentiment: A recent bullish take on Pfizer argues the company’s longer-term fundamentals and pipeline still support a positive view, which can provide investor confidence despite near-term headwinds. Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance
• Neutral Sentiment: Analyst commentaries and market-roundup pieces are providing mixed views on valuation and peer comparisons; these flow into investor expectations but are not single-driver news. Analysts Offer Insights on Healthcare Companies: Pfizer (PFE)
• Neutral Sentiment: Profiles of CEO strategy and company direction are keeping Pfizer in investor conversation but are background/PR-level items rather than immediate price drivers. Pfizer’s CEO on leading after a moonshot—and making deals with Trump
• Negative Sentiment: The U.S. Centers for Medicare & Medicaid Services included Pfizer products on the third-cycle Medicare Drug Price Negotiation list — a structural risk that could pressure pricing and future revenue for the named drugs. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: Earnings previews suggest Q4 results could show declining EPS, and Pfizer flagged a modest FY2025 EPS guidance range, keeping near-term growth expectations muted. That raises the risk of an earnings-driven pullback when the quarter is reported. Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline
• Negative Sentiment: Competitive risk: Aclaris reported preclinical results suggesting its hair-loss candidate may show faster results than Pfizer’s Litfulo in early testing—an example of execution/competition risk in therapeutic franchises. Aclaris Hair Loss Drug Shows Faster Results Than Pfizer’s Drug
• Negative Sentiment: Coverage on Pfizer’s balance sheet highlights heavier use of debt measures versus peers, which could be a concern if growth stalls. (Note: PFE’s reported debt/equity is ~0.62.) These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.